Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
Precision Drilling
PDS
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 2.65%1.72B | 3.30%437.81M | 4.07%428.15M | 1.76%426.29M | 1.49%423.43M | -1.11%1.67B | -0.04%423.84M | -0.75%411.39M | -1.39%418.93M | -2.24%417.23M |
Operating revenue | 2.65%1.72B | 3.30%437.81M | 4.07%428.15M | 1.76%426.29M | 1.49%423.43M | -1.11%1.67B | -0.04%423.84M | -0.75%411.39M | -1.39%418.93M | -2.24%417.23M |
Cost of revenue | 2.12%1.49B | 8.62%379.21M | -3.24%364.73M | 4.49%384.74M | -0.96%358.91M | -2.69%1.46B | -4.96%349.12M | 0.01%376.94M | -2.94%368.2M | -2.92%362.38M |
Gross profit | 6.21%228.09M | -21.57%58.6M | 84.08%63.42M | -18.10%41.55M | 17.63%64.52M | 11.09%214.75M | 31.82%74.72M | -8.36%34.45M | 11.52%50.73M | 2.43%54.85M |
Operating expense | 9.20%174.82M | 5.11%44.35M | 10.38%44.47M | 10.44%43.19M | 11.19%42.81M | 7.07%160.09M | 12.89%42.2M | 9.00%40.29M | 9.66%39.1M | -2.58%38.5M |
Selling and administrative expenses | 9.20%174.82M | 5.11%44.35M | 10.38%44.47M | 10.44%43.19M | 11.19%42.81M | 7.07%160.09M | 12.89%42.2M | 9.00%40.29M | 9.66%39.1M | -2.58%38.5M |
Operating profit | -2.54%53.27M | -56.18%14.25M | 424.65%18.95M | -114.12%-1.64M | 32.79%21.71M | 24.82%54.66M | 68.48%32.52M | -1,025.04%-5.84M | 18.29%11.62M | 16.55%16.35M |
Net non-operating interest income expense | 18.05%-6.44M | 42.76%-1.18M | 27.39%-1.55M | 10.39%-1.72M | -13.99%-2M | -163.01%-7.86M | -66.64%-2.06M | -166.83%-2.13M | -330.34%-1.92M | -244.01%-1.75M |
Non-operating interest expense | -18.05%6.44M | -42.76%1.18M | -27.39%1.55M | -10.39%1.72M | 13.99%2M | 163.01%7.86M | 66.64%2.06M | 166.83%2.13M | 330.34%1.92M | 244.01%1.75M |
Other net income (expense) | -2.33%6.11M | -5.72%1.73M | -14.06%1.41M | 11.92%1.37M | 2.76%1.6M | 66.73%6.25M | 25.74%1.84M | 40.91%1.64M | 208.22%1.23M | -31.21%1.56M |
Gain on sale of security | -2.33%6.11M | -5.72%1.73M | -14.06%1.41M | 11.92%1.37M | 2.76%1.6M | 66.73%6.25M | 25.74%1.84M | 40.91%1.64M | 208.22%1.23M | -31.21%1.56M |
Income before tax | -0.22%52.94M | -54.16%14.81M | 396.98%18.81M | -118.16%-1.99M | 31.93%21.31M | 19.09%53.06M | 65.40%32.3M | -737.76%-6.33M | 32.53%10.93M | 2.37%16.16M |
Income tax | -8.18%13.47M | -67.19%2.89M | 471.54%4.78M | -107.39%-198K | 33.92%6.01M | 42.29%14.67M | 134.02%8.79M | -291.65%-1.29M | 87.41%2.68M | 0.72%4.48M |
Net income | 2.83%39.47M | -49.29%11.92M | 377.99%14.03M | -121.66%-1.79M | 31.17%15.31M | 12.10%38.39M | 49.05%23.51M | -1,667.39%-5.05M | 21.03%8.25M | 3.02%11.67M |
Net income continuous Operations | 2.83%39.47M | -49.29%11.92M | 377.99%14.03M | -121.66%-1.79M | 31.17%15.31M | 12.10%38.39M | 49.05%23.51M | -1,667.39%-5.05M | 21.03%8.25M | 3.02%11.67M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 2.83%39.47M | -49.29%11.92M | 377.99%14.03M | -121.66%-1.79M | 31.17%15.31M | 12.10%38.39M | 49.05%23.51M | -1,667.39%-5.05M | 21.03%8.25M | 3.02%11.67M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 2.83%39.47M | -49.29%11.92M | 377.99%14.03M | -121.66%-1.79M | 31.17%15.31M | 12.10%38.39M | 49.05%23.51M | -1,667.39%-5.05M | 21.03%8.25M | 3.02%11.67M |
Basic earnings per share | 3.85%0.54 | -48.39%0.16 | 371.43%0.19 | -118.18%-0.02 | 31.25%0.21 | 13.04%0.52 | 40.91%0.31 | -1,716.25%-0.07 | 22.22%0.11 | 6.67%0.16 |
Diluted earnings per share | 1.92%0.53 | -48.39%0.16 | 371.43%0.19 | -118.18%-0.02 | 31.25%0.21 | 13.04%0.52 | 40.91%0.31 | -1,716.25%-0.07 | 22.22%0.11 | 6.67%0.16 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- | -- |